Holen Sie sich die Stockscreener-App
24.90
0.73%
0.18
Vorhandelsmarkt:
24.88
-0.02
-0.08%
Schlusskurs vom Vortag:
$24.72
Offen:
$24.71
24-Stunden-Volumen:
769.36K
Relative Volume:
0.97
Marktkapitalisierung:
$1.01B
Einnahmen:
$726.41M
Nettoeinkommen (Verlust:
$7.03M
KGV:
158.50
EPS:
0.1571
Netto-Cashflow:
$136.66M
1W Leistung:
+3.49%
1M Leistung:
+12.62%
6M Leistung:
+8.17%
1J Leistung:
+1.01%
1-Tages-Spanne:
$24.57
$25.32
1-Wochen-Bereich:
$23.10
$25.32
52-Wochen-Spanne:
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
650-242-8052
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
24.90 | 1.01B | 726.41M | 7.03M | 136.66M | 0.1571 |
TAK
Takeda Pharmaceutical Co Adr
|
17.55 | 55.44B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
122.72 | 51.61B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.68 | 43.06B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.02 | 37.28B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
573.44 | 25.13B | 3.18B | 1.33B | 1.04B | 27.90 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-25 | Hochstufung | Truist | Hold → Buy |
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
[144] Pacira BioSciences, Inc. SEC Filing - Stock Titan
Can New EXPAREL Data and Proxy Fight Outcomes Reshape the Case For Investing In Pacira (PCRX)? - Yahoo Finance
Pacira (PCRX) BioSciences well-positioned with genicular outcomes registry evidence - MSN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. LawsuitPCRX - ACCESS Newswire
Pacira (NASDAQ: PCRX) pushes BLUE proxy, flags 2026 pipeline and repurchases - Stock Titan
2026-04-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026 - markets.businessinsider.com
Pacira will post quarterly results after market close on April 30 - Stock Titan
PCRX: EXPAREL growth, new partnerships, and pipeline milestones set the stage for double-digit gains - TradingView
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Pacira (PCRX) Data Highlights Cost Benefits and Opioid Reduction - GuruFocus
Pacira BioSciences, Inc. Presents Real-World Data On EXPAREL Showing Lower Total Healthcare Costs In Outpatient Total Hip And Knee Arthroplasty Procedures - marketscreener.com
Pacira (PCRX) Highlights Economic Benefits of Exparel in Orthope - GuruFocus
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures - marketscreener.com
Pacira Presents Real-World Data on EXPAREL® Showing Lower - GlobeNewswire
(PCRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Investment Recap: Can Pacira BioSciences Inc expand its profit marginsWeekly Trade Report & Risk Controlled Daily Plans - baoquankhu1.vn
PCRX.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Weekly Earnings: Is Pacira BioSciences Inc stock a falling knife or bargain buy2026 Outlook & Risk Managed Investment Strategies - baoquankhu1.vn
PCRX.O Technical Analysis & Stock Price Forecast - Intellectia AI
Dimensional Fund Advisors (NASDAQ: PCRX) reports 2.06M shares owned - Stock Titan
Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo Finance
Pacira BioSciences | SCHEDULE 13G: Others - Moomoo
PCRX Should I Buy - Intellectia AI
PCRX.O PE Ratio & Valuation, Is PCRX.O Overvalued - Intellectia AI
PCRX News & Events - Intellectia AI
Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Pacira investors get live access to Needham healthcare event April 15 - Stock Titan
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation | NDAQ:PCRX | Press Release - Stockhouse
PCRX Technical Analysis & Stock Price Forecast - Intellectia AI
PCRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
2026-04-02 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences, Inc. (PCRX) Stock forecasts - Yahoo Finance UK
Analysts Set Expectations for PCRX Q1 Earnings - MarketBeat
(PCRX) Risk Channels and Responsive Allocation - Stock Traders Daily
2026-03-31 | Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira (PCRX) BioSciences Well-Positioned With Genicular Outcomes Registry Evidence - Insider Monkey
Hennion & Walsh Asset Management Inc. Acquires 87,210 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Present Real-World Data on EXPAREL Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting - Bitget
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting - Ortho Spine News
Study data linked EXPAREL to lower knee and spine surgery costs - Stock Titan
Pacira BioSciences to Present Real-World Data on EXPAREL® - GlobeNewswire
2026-03-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences, Inc. $PCRX Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Bull Run: Is Pacira BioSciences Inc impacted by rising ratesQuarterly Profit Report & Expert Curated Trade Ideas - baoquankhu1.vn
Vanguard amends Schedule 13G/A after internal realignment (PCRX) - stocktitan.net
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
2026-03-26 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences (NASDAQ:PCRX) Price Target Cut to $25.00 by Analysts at Barclays - MarketBeat
PCRX: Barclays Lowers Price Target to $25, Maintains Equal-Weigh - GuruFocus
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.58%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):